Lyn S. Pilowsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lyn S. Pilowsky has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Caroline Stephenson
1 shared publicationDimitris Visvikis
1 shared publicationH. M. Jones
1 shared publicationPaul D. Acton
1 shared publicationPeter J. Ell
1 shared publication- Philip Shaw
Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
1 shared publication
Latest Publications
- Open Access
- 1 October 2002
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 181 (4) , 271-275
Dopamine and antipsychotic drug action revisited
- 1 October 2002
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 181 (4) , 271-275
Open AccessDopamine and antipsychotic drug action revisited
- 1 July 2001
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 22 (7) , 829-833
Probing targets for antipsychotic drug action with PET and SPET receptor imaging
The use of in vivo receptor imaging by positron emission tomography (PET) and single photon emission tomography (SPET) has permitted exploration of targets for antipsychotic drug action in living patients. Early PET and SPET studies focused on striatal D2 dopamine receptors. There is broad agreement that unwanted extrapyramidal (parkinsonian) side effects of antipsychotic drugs result from high striatal dopamine D2/D3 receptor blockade by these drugs. The dopamine hypothesis of antipsychotic drug action suggests that clinical response is directly related to the level of striatal D2/D3 receptor occupancy of antipsychotic drugs. This may be true for classical antipsychotic drugs, but recent evidence suggests that novel, atypical antipsychotic drugs produce efficacy in association with modest and transient striatal D2/D3 receptor occupancy levels. Furthermore, atypical antipsychotic drugs appear to show preferential occupancy of limbic cortical dopamine D2 receptors. Cortical dopamine D2/D2-like receptors may be a common site of action for all antipsychotic drugs. Data from receptor challenge paradigms has highlighted the need to explore the neurotransmitter systems involved in regulating or stabilising dopamine transmission, either via dopamine autoreceptors or non-dopaminergic pathways. These may be promising targets for drug development. In vivo PET and SPET imaging has produced unique data contributing to the design of better, less toxic drugs for schizophrenia.
- 1 July 2001
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 22 (7) , 829-833
Probing targets for antipsychotic drug action with PET and SPET receptor imaging
The use of in vivo receptor imaging by positron emission tomography (PET) and single photon emission tomography (SPET) has permitted exploration of targets for antipsychotic drug action in living patients. Early PET and SPET studies focused on striatal D2 dopamine receptors. There is broad agreement that unwanted extrapyramidal (parkinsonian) side effects of antipsychotic drugs result from high striatal dopamine D2/D3 receptor blockade by these drugs. The dopamine hypothesis of antipsychotic drug action suggests that clinical response is directly related to the level of striatal D2/D3 receptor occupancy of antipsychotic drugs. This may be true for classical antipsychotic drugs, but recent evidence suggests that novel, atypical antipsychotic drugs produce efficacy in association with modest and transient striatal D2/D3 receptor occupancy levels. Furthermore, atypical antipsychotic drugs appear to show preferential occupancy of limbic cortical dopamine D2 receptors. Cortical dopamine D2/D2-like receptors may be a common site of action for all antipsychotic drugs. Data from receptor challenge paradigms has highlighted the need to explore the neurotransmitter systems involved in regulating or stabilising dopamine transmission, either via dopamine autoreceptors or non-dopaminergic pathways. These may be promising targets for drug development. In vivo PET and SPET imaging has produced unique data contributing to the design of better, less toxic drugs for schizophrenia.
- Open Access
- 1 January 2000
- Published by Hindawi Limited in Behavioural Neurology
- Vol. 12 (1-2) , 3-9
Probing Cortical Sites of Antipsychotic Drug Action within vivoReceptor Imaging
Imaging receptors using radioactive ligands has allowed direct determination of the sites of action of antipsychotic drugs. Initial studies relating antipsychotic drug efficacy to action at striatal dopamine D2-like receptors have recently been undermined. Developments in imaging extrastriatal dopamine D2-like receptors suggest rather that antagonism of these receptors in the temporal cortex is the common site of action for antipsychotic drugs, with occupancy at striatal receptors relating more closely to extrapyramidal side effects. Further work into dopamine receptor subtypes and other receptor groups such as serotonin and GABA neurotransmitters awaits the development of suitable probes, but there are some initial finding. Again a main site of antipsychotic drug action is at cortical levels with high degrees of cortical D1 and 5HT2a receptor occupancy attained particularly by atypical antipsychotic drugs.
- 1 January 2000
- Published by Hindawi Limited in Behavioural Neurology
- Vol. 12 (1-2) , 3-9
Open AccessProbing Cortical Sites of Antipsychotic Drug Action within vivoReceptor Imaging
Imaging receptors using radioactive ligands has allowed direct determination of the sites of action of antipsychotic drugs. Initial studies relating antipsychotic drug efficacy to action at striatal dopamine D2-like receptors have recently been undermined. Developments in imaging extrastriatal dopamine D2-like receptors suggest rather that antagonism of these receptors in the temporal cortex is the common site of action for antipsychotic drugs, with occupancy at striatal receptors relating more closely to extrapyramidal side effects. Further work into dopamine receptor subtypes and other receptor groups such as serotonin and GABA neurotransmitters awaits the development of suitable probes, but there are some initial finding. Again a main site of antipsychotic drug action is at cortical levels with high degrees of cortical D1 and 5HT2a receptor occupancy attained particularly by atypical antipsychotic drugs.
- 1 September 1999
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 175 (3) , 231-238
In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs
Background: The dopamine hypothesis proposes that antipsychotic drugs act primarily through limbic cortical D2/D2-like dopamine receptor blockade.Aim: To evaluate this hypothesis with the D2/D3-selective SPET probe [123I]-epidepride.Method: [123I]-epidepride SPETscans were performed on 12 patients with schizophrenia treated with antipsychotics and 11 age-matched healthy controls. [123I]-epidepride specific binding to D2/D3 dopamine receptors was estimated, and relative percentage D2/D3 receptor occupancy by typical antipsychotic drugs determined.Results: Mean (s.d.) daily dose was 669.12 (516.8) mg chlorpromazine equivalents. Mean percentage D2/D3 receptor occupancy was 81.6 (8.1) and 73.2 (13.9) in the temporal cortex and striatum respectively.Conclusions: Typical antipsychotic drug treatment is associated with substantial temporal cortical D2/D3 receptor occupancy. The relationship between this and efficacy is poor in patients with treatment-resistant schizophrenia.
- 1 September 1999
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 175 (3) , 231-238
In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs
Background: The dopamine hypothesis proposes that antipsychotic drugs act primarily through limbic cortical D2/D2-like dopamine receptor blockade.Aim: To evaluate this hypothesis with the D2/D3-selective SPET probe [123I]-epidepride.Method: [123I]-epidepride SPETscans were performed on 12 patients with schizophrenia treated with antipsychotics and 11 age-matched healthy controls. [123I]-epidepride specific binding to D2/D3 dopamine receptors was estimated, and relative percentage D2/D3 receptor occupancy by typical antipsychotic drugs determined.Results: Mean (s.d.) daily dose was 669.12 (516.8) mg chlorpromazine equivalents. Mean percentage D2/D3 receptor occupancy was 81.6 (8.1) and 73.2 (13.9) in the temporal cortex and striatum respectively.Conclusions: Typical antipsychotic drug treatment is associated with substantial temporal cortical D2/D3 receptor occupancy. The relationship between this and efficacy is poor in patients with treatment-resistant schizophrenia.